Table 1.
Clinical characteristics per subtype and treatment of 583 patients
| All (n = 583) | Luminal A (n = 127, 21.8%) | Luminal B (n = 275, 47.2%) | HER2‐positive (n = 103, 17.7%) | TNBC (n = 78, 13.4%) | |
|---|---|---|---|---|---|
|
Age at diagnosis >50 y, No. (%) |
277 (47.5%) | 54 (42.5%) | 132 (48%) | 54 (52.4%) | 37 (47.3%) |
| Median (minimum, maximum) | 50 (25, 76) | 49 (28, 72) | 50 (27, 76) | 52 (25, 71) | 49 (27, 72) |
| Menopausal status, No. (%) | |||||
| Pre‐ | 289 (49.6%) | 71 (55.9%) | 137 (49.8%) | 48 (46.6%) | 33 (42.3%) |
| Post‐ | 273 (46.8%) | 54 (42.5%) | 129 (46.9%) | 50 (48.5%) | 40 (51.3%) |
| Unknown | 21 (3.6%) | 2 (1.6%) | 9 (3.3%) | 5 (4.9%) | 5 (6.4%) |
| Pathology, No. (%) | |||||
| IDC | 570 (97.8%) | 123 (96.9%) | 268 (97.5%) | 102 (99.0%) | 77 (98.7%) |
| ILC | 12 (2.1%) | 4 (3.1%) | 6 (2.2%) | 1 (1.0%) | 1 (1.3%) |
| Other | 1 (0.2%) | 0 (0) | 1 (0.4) | 0 (0%) | 0 (0) |
| Grade, No. (%) | |||||
| 1‐2 | 297 (50.9%) | 92 (72.4%) | 150 (54.5%) | 36 (35.0%) | 19 (24.4%) |
| 3 | 167 (28.6%) | 23 (18.1%) | 74 (26.9%) | 34 (33.0%) | 36 (46.2%) |
| Unknown | 119 (20.4%) | 12 (9.4%) | 51 (18.5%) | 33 (32.0%) | 23 (29.5%) |
| LVI, No. (%) | |||||
| Yes | 375 (64.3%) | 97 (76.4%) | 179 (65.1%) | 57 (55.3%) | 42 (53.8%) |
| No | 163 (28.0%) | 27 (21.3%) | 80 (29.1%) | 29 (28.2%) | 27 (34.6%) |
| Unknown | 45 (7.7%) | 3 (2.4%) | 16 (5.8%) | 17 (16.5%) | 9 (11.5%) |
| T stage, No. (%) | |||||
| T1‐2 | 494 (84.7%) | 122 (96.1%) | 236 (85.8%) | 80 (77.7%) | 56 (71.8%) |
| T3 | 23 (3.9%) | 2 (1.6%) | 12 (4.4%) | 5 (4.9%) | 4 (5.1%) |
| Tx | 66 (11.3%) | 3 (2.4%) | 27 (9.8%) | 18 (17.5%) | 18 (23.1%) |
| N stage, No. (%) | |||||
| N0 | 77 (13.2%) | 7 (5.5%) | 29 (10.5%) | 24 (23.3%) | 17 (21.8%) |
| N1 | 220 (37.7%) | 47 (37.0%) | 108 (39.3%) | 36 (35.0%) | 29 (37.2%) |
| N2 | 148 (25.4%) | 38 (30.0%) | 76 (27.6%) | 21 (20.4%) | 13 (16.7%) |
| N3 | 138 (23.7%) | 35 (27.6%) | 62 (22.5%) | 22 (21.4%) | 19 (24.4%) |
| Breast surgery, No. (%) | |||||
| Mastectomy | 583 (100%) | 127 (100%) | 275 (100%) | 103 (100%) | 78 (100%) |
| Radiotherapy, No. (%) | |||||
| Yes | 583 (100%) | 127 (100%) | 275 (100%) | 103 (100%) | 78 (100%) |
| Chemotherapy, No. (%) | |||||
| Yes | 548 (94.0%) | 118 (92.9%) | 259 (94.2%) | 96 (93.2%) | 75 (96.2%) |
| No | 35 (6%) | 9 (7.1%) | 16 (5.8%) | 7 (6.8%) | 3 (3.8%) |
| Hormone therapy, No. (%) | |||||
| Yes | 392 (67.2%) | 116 (91.3%) | 238 (86.5%) | 34 (33.0%) | 4 (5.1%) |
| No | 191 (32.8%) | 11 (8.7%) | 37 (13.5%) | 69 (67.0%) | 74 (94.9%) |
| Trastuzumab, No. (%) | |||||
| Yes | 114 (19.6%) | 1 (0.8%) | 58 (21.1%) | 55 (53.4%) | 0 (0) |
| No | 469 (80.4%) | 126 (99.2%) | 217 (78.9%) | 48 (46.6%) | 78 (100%) |
Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphatic vessel invasion; TNBC, triple‐negative breast cancer